Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Amortizatization of Intangibles (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Amortizatization of Intangibles data on record, last reported at $459000.0 in Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 12.4% year-over-year to $459000.0; the TTM value through Sep 2025 reached $1.3 million, up 29.24%, while the annual FY2024 figure was $1.1 million, 27.63% up from the prior year.
  • Amortizatization of Intangibles reached $459000.0 in Q3 2025 per CRVS's latest filing, up from $334000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $524000.0 in Q3 2024 and bottomed at -$83000.0 in Q3 2022.
  • Average Amortizatization of Intangibles over 4 years is $219266.7, with a median of $242000.0 recorded in 2024.
  • Peak YoY movement for Amortizatization of Intangibles: surged 545.0% in 2023, then tumbled 42.8% in 2024.
  • A 4-year view of Amortizatization of Intangibles shows it stood at $158000.0 in 2022, then dropped by 19.62% to $127000.0 in 2023, then soared by 90.55% to $242000.0 in 2024, then surged by 89.67% to $459000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $459000.0 in Q3 2025, $334000.0 in Q2 2025, and $291000.0 in Q1 2025.